Drug Profile
Research programme: neuropeptide Y antagonists - Neurogen
Latest Information Update: 24 Aug 2004
Price :
$50
*
At a glance
- Originator Neurogen Corporation
- Class
- Mechanism of Action Neuropeptide Y receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Major depressive disorder; Obesity
Most Recent Events
- 24 Aug 2004 Discontinued - Preclinical for Obesity in USA (unspecified route)
- 11 Jan 2001 Discontinued-Preclinical for Depression in USA (Unknown route)
- 11 Feb 1999 Preclinical development for Obesity in USA (Unknown route)